0 Valeant Pharmaceuticals Intl Analyst Ratings, Earnings, Dividends and Insider Trades | $VRX | NYSE:VRX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Valeant Pharmaceuticals Intl Company Profile (NYSE:VRX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:VRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 13 Buy Rating(s), 1 Strong Buy Rating(s)Consensus Rating:Buy (Score: 2.94)Consensus Price Target: $139.53 0.86% downside) Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:VRX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/28/2014UBS AGBoost Price TargetBuy$141.00 -> $170.00View 2/28/2014RBC CapitalBoost Price TargetOutperform$151.00 -> $158.00View 2/27/2014JPMorgan Chase & Co.Boost Price Target$140.00 -> $170.00View 2/27/2014AegisBoost Price TargetBuy$160.00 -> $180.00View 2/19/2014BMO Capital MarketsBoost Price Target$149.00 -> $162.00View 1/8/2014UBS AGBoost Price TargetBuy$125.00 -> $141.00View 1/8/2014TD SecuritiesDowngradeBuy -> HoldView 1/8/2014Ladenburg ThalmannBoost Price TargetBuy$123.00 -> $155.00View 1/8/2014FBR Capital MarketsBoost Price TargetOutperform$130.00 -> $153.00View 1/8/2014Morgan StanleyUpgradeEqual Weight -> Overweight$145.00View 1/8/2014JPMorgan Chase & Co.Boost Price Target$125.00 -> $140.00View 1/8/2014BMO Capital MarketsBoost Price Target$132.00 -> $146.00View 12/17/2013Canaccord GenuityBoost Price Target$115.00 -> $119.00View 12/3/2013UBS AGBoost Price TargetBuy$115.00 -> $125.00View 11/6/2013ZacksDowngradeOutperform -> Neutral$116.40View 11/1/2013Ladenburg ThalmannLower Price TargetBuy$127.00 -> $123.00View 10/31/2013Goldman SachsReiterated RatingConviction-Buy$130.00View 10/30/2013FBR Capital MarketsInitiated CoverageOutperform$130.00View 10/28/2013AegisReiterated RatingBuy -> PositiveView 10/8/2013ZacksUpgradeNeutral -> Outperform$112.40View 10/7/2013CRT CapitalBoost Price TargetBuy$110.00 -> $130.00View 10/2/2013BMO Capital MarketsSet Price Target$109.00 -> $123.00View 9/26/2013GuggenheimInitiated CoverageBuyView 9/17/2013Goldman SachsInitiated CoverageNeutral -> Conviction-Buy$130.00View 8/8/2013UBS AGBoost Price TargetBuy$96.00 -> $115.00View 8/8/2013JPMorgan Chase & Co.Initiated CoverageOverweightView 8/7/2013AegisBoost Price TargetBuy$135.00 -> $140.00View 7/31/2013ZacksDowngradeOutperform -> Neutral$96.80View 7/8/2013Deutsche BankReiterated RatingBuy$103.00 -> $104.00View 7/2/2013ZacksUpgradeNeutral -> Outperform$92.80View 7/2/2013RBC CapitalBoost Price TargetOutperform$76.00 -> $100.00View 6/28/2013Canaccord GenuityLower Price TargetBuyC$112.00 -> C$110.00View 6/10/2013CRT CapitalUpgradeFair Value -> Buy$100.00View 5/31/2013BMO Capital MarketsInitiated CoverageOutperformView 5/29/2013Ladenburg ThalmannBoost Price TargetBuy$84.00 -> $124.00View 5/29/2013Jefferies GroupBoost Price TargetBuy$77.00 -> $120.00View 5/28/2013UBS AGReiterated RatingBuy$81.00View 5/28/2013Deutsche BankReiterated RatingBuy$82.00 -> $103.00View 5/28/2013SusquehannaBoost Price TargetPositiveC$84.00 -> C$105.00View 5/28/2013Paradigm CapitalBoost Price TargetBuyC$82.00 -> C$115.00View 5/28/2013TD SecuritiesBoost Price TargetBuy$85.00 -> $117.00View 5/3/2013Deutsche BankBoost Price TargetBuy$80.00 -> $82.00View 4/4/2013UBS AGLower Price TargetBuy$83.00 -> $81.00View 4/4/2013RBC CapitalLower Price TargetOutperform$80.00 -> $76.00View 3/27/2013Ameriprise FinancialInitiated CoverageBuyView 3/21/2013Paradigm CapitalReiterated RatingBuy$83.00 -> $35.00View 3/21/2013Deutsche BankReiterated RatingBuy$77.00 -> $83.00View 3/21/2013RBC CapitalBoost Price Target$70.00 -> $80.00View 3/20/2013Jefferies GroupReiterated RatingBuyView 3/20/2013AegisReiterated RatingBuyView 3/20/2013JPMorgan Chase & Co.Reiterated RatingOverweightView 3/20/2013Morgan StanleyReiterated RatingEqual WeightView 3/20/2013TD SecuritiesBoost Price TargetBuy$77.00 -> $85.00View 3/1/2013Deutsche BankReiterated RatingBuy$77.00View 3/1/2013Paradigm CapitalBoost Price TargetBuy$72.00 -> $83.00View 3/1/2013Ladenburg ThalmannBoost Price TargetBuy$75.00 -> $84.00View 2/22/2013AegisInitiated CoverageBuy$80.00View 1/7/2013Deutsche BankReiterated RatingBuy$75.00 -> $77.00View 1/7/2013Lazard Ltd.Lower Price TargetBuy$79.00 -> $72.00View 12/17/2012Deutsche BankBoost Price TargetBuy$62.00 -> $75.00View 12/12/2012TD SecuritiesBoost Price TargetBuy$75.00 -> $77.00View 12/12/2012JPMorgan Chase & Co.Initiated CoverageOverweight$75.00View 10/24/2012Paradigm CapitalLower Price Target$67.00View 10/11/2012Stifel NicolausBoost Price TargetBuy$60.00 -> $75.00View 9/14/2012Morgan StanleyDowngradeOverweight -> Equal WeightView 9/7/2012Jefferies GroupBoost Price TargetBuy$63.00 -> $77.00View 9/5/2012TD SecuritiesBoost Price TargetBuy$65.00 -> $75.00View 9/5/2012Canaccord GenuityBoost Price TargetBuy$62.00 -> $70.00View 9/5/2012Ladenburg ThalmannBoost Price TargetBuy$62.00 -> $67.00View 9/4/2012UBS AGReiterated RatingBuy$64.00 -> $65.00View 8/3/2012Piper JaffrayBoost Price TargetNeutral$52.00 -> $53.00View 7/13/2012Goldman SachsInitiated CoverageNeutralView 6/22/2012Jefferies GroupCut EstimatesBuy$75.00 -> $63.00View 5/7/2012Morgan StanleyBoost Price TargetOverweight$61.00View 5/3/2012CRT CapitalDowngradeBuyView (Data available from 3/12/2012 forward) Earnings History for Valeant Pharmaceuticals Intl (NYSE:VRX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView 10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView 8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView 5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView 2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView 11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView 8/2/2012$0.99$1.01ViewN/AView 5/3/2012$0.96$0.99ViewN/AView 11/3/2011$0.57$0.66ViewN/AView 8/4/2011$0.65$0.73ViewN/AView 5/9/2011$0.51$0.56ViewN/AView 2/24/2011$0.45$0.51ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Valeant Pharmaceuticals Intl (NYSE:VRX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:VRX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View 1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View 1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View 12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View 11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View 11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View 9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View 9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View 9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View 8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View 8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View 8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View 8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View 8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View 6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View 6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View 6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View 3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View 11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View 11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View (Data available from 1/1/2013 forward) About Valeant Pharmaceuticals Intl Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. On December 12, 2011, it acquired assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. (Janssen). In August 2013, Valeant Pharmaceuticals International Inc completed the acquisition of Bausch + Lomb Holdings Incorporated. In January 2014, the Company's wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc. Industry, Sector and Symbol: Sector: Healthcare Industry: N/A Sub-Industry: N/A Exchange: NYSE Symbol: VRX CUSIP: Key Metrics: Previous Close: $140.7450 Day Moving Average: $139.978200 Day Moving Average: $117.379 P/E Ratio: N/AP/E Growth: 1.09Market Cap: $46.868BCurrent Quarter EPS Consensus Estimate: $8.68 EPS Additional Links: View VRX on Google FinanceView VRX on Yahoo FinanceView VRX's Company Profile on ReutersSearch for Valeant Pharmaceuticals Intl Inc on Google Valeant Pharmaceuticals Intl (NYSE:VRX) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.